Brief TOC
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6 Global Antihistamine drugs Market, by Type
6.1 Introduction
6.2 Sedating Antihistamine Drugs
6.2.1 Brompheniramine
6.2.2 Chlorpheniramine
6.2.3 Diphenhydramine
6.2.4 Doxylamine
6.2.5 Carbinoxamine
6.2.6 Others
6.3 Non-Sedating Antihistamine Drugs
6.3.1 Fexofenadine
6.3.2 Loratadine
6.3.3 Loratadine ODT
6.3.4 Others
7 Global Antihistamine Drugs Market, By Route of Administration
7.1 Introduction
7.2 Oral Route
7.3 Parenteral Route
7.3.1 Intramuscular
7.3.2 Subcutaneous
7.3.3 Intravenous Route
7.4 Rectal Route
8 Global Antihistamine Drugs Market, by Indication
8.1 Introduction
8.2 Allergy
8.3 Urticaria
8.4 Dermatitis
8.5 Others
9 Global Antihistamine Drugs Market by End User
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Pharmaceutical Companies
9.5 Others
10 Global Antihistamine Drugs Market by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Republic of Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Johnson & Johnson Consumer Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Sanofi
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Bayer AG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Pfizer
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Merck Sharp & Dohme Corp.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.6 Prestige Brands Holdings, Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 CVS Pharmacy
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical Industry
14 Appendix